KHRNF - Khiron Life Sciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.6200
-0.0900 (-5.26%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close1.7100
Open1.7300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.6049 - 1.7300
52 Week Range0.6637 - 3.2800
Volume133,544
Avg. Volume195,055
Market Cap178.714M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group7 days ago

    Khiron Obtains Final Approval to Commercialize CBD Production and Receives Approval for an additional 17 Cannabis Strains from Colombian Agricultural Institute

    Khiron has now secured all approvals required to commercialize current CBD cultivation and production for medical purposes. Khiron has now registered a total of 22 strains with Colombian Agricultural Institute ("ICA"). TORONTO, July 17, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has received approval from the National Cultivar Registry and the Technical Direction of the ICA for the commercialization of 17 stains of cannabis.

  • CNW Group8 days ago

    Khiron Targets Over 40,000 Beauty Industry Leaders with Kuida Skin Care Brand at Cosmoprof North America

    Full portfolio of Kuida products will be exhibited at the event's Discover Beauty Pavilion to over 40,000 retail buyers, distributors, and beauty industry professionals Kuida is the first Colombian mass-market ...

  • CNW Group9 days ago

    Khiron Provides Corporate Update on Commercial and Operational Activities

    Colombia commercial production anticipated to be commercialized in Q3. Wellness line secured distribution agreements with largest retails of product category throughout Colombia, across 176 points of sale. TORONTO, July 15, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to provide a corporate update on core commercial and operational activities.

  • CNW Group15 days ago

    Khiron CEO Alvaro Torres to Present at 2019 Canaccord Genuity U.S. Annual Growth Conference

    TORONTO, July 9, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, announced today that the Company will be presenting at the 39th annual Canaccord Genuity Growth Conference, taking place in Boston, MA, August 7-8, 2019.

  • CNW Group16 days ago

    Khiron Leads Cannabis Education at XLIV International Course of Internal Medicine, Reaching Over 2,000 Medical Specialists in Mexico

    TORONTO, July 8, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced today its participation in the XLIV International Course of Internal Medicine conference, which took place from July 3-6 in Monterrey, Mexico. Organized by the Mexican College of Internal Medicine, Khiron was the only cannabis company to participate in this year's conference, where it joined over 2000 physicians and medical specialists to inform, educate and discuss medical cannabis knowledge and developments.

  • CNW Group21 days ago

    Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , July 3, 2019 /CNW/ - Virtual Investor Conferences, in ...

  • CNW Group23 days ago

    Khiron Welcomes EU Trade Deal with Latin American Countries

    TORONTO, July 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, applauds the EU-Mercosur Trade Agreement announced between the European Union and Mercosur, the Latin American trading block made up of Argentina, Brazil, Uruguay and Paraguay. Khiron is active among Mercosur jurisdictions with a recently completed acquisition of NettaGrowth International, a cannabis company based in Uruguay.

  • CNW Group29 days ago

    Khiron President Chris Naprawa to Participate in Grit Capital Virtual Investor Conference

    TORONTO, June 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, announces today that Company president Chris Naprawa will be presenting at the Grit Capital Virtual Investor Conference to be hosted on June 26, 2019. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis.

  • CNW Grouplast month

    Grit Capital's Live-Stream Virtual Investor Conference June 26th

    9 Company Executives of small cap millennial themed companies share their vision and answer questions live at VirtualInvestorConferences.com NEW YORK , June 21, 2019 /CNW/ - Virtual Investor Conferences, ...

  • CNW Grouplast month

    Khiron Completes Acquisition of NettaGrowth International Advancing Multi-Country Operator Strategy

    TORONTO, June 19, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, announces that it has completed the acquisition of NettaGrowth International Inc. ("NettaGrowth"), previously announced on January 25, 2019 and April 9, 2019, and its wholly-owned subsidiary Dormul S.A. ("Dormul"), a Uruguayan company that has obtained the first licence to produce and export medical cannabis with THC for commercialization in Uruguay. As consideration for the acquisition of NettaGrowth, Khiron has issued 8,498,821 common shares to the shareholders of NettaGrowth at a deemed price of $1.61 per common share.

  • ACCESSWIRElast month

    Khiron Life Sciences Corp. Joins the Stock Day Podcast to Discuss Expansion in Latin America

    PHOENIX, AZ / ACCESSWIRE / June 17, 2019 / The Stock Day Podcast welcomed Khiron Life Sciences Corp. (KHRNF) ("the Company"), a vertically integrated cannabis leader with core operations in Latin America. President of the Company, Chris Naprawa, joined Stock Day host Everett Jolly to discuss the Company's recent closing of a $28 million financing round, and its rapid expansion across new markets. Jolly began the interview by asking about the Company's closing of the aforementioned financing deal.

  • CNW Grouplast month

    Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO

    TORONTO, June 14, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019. Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.

  • CNW Group2 months ago

    Khiron Receives Regulatory Approval for Uruguay Acquisition

    TORONTO, June 7, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned. On June 5, 2019, the Company secured local regulatory approvals in Uruguay for the completion of the Acquisition.

  • CNW Group2 months ago

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , June 6, 2019 /CNW/ - Virtual Investor Conferences ...

  • /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/
    CNW Group2 months ago

    /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/

    TORONTO, June 2, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year
    CNW Group2 months ago

    Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year

    TORONTO, June 2, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • CNW Group2 months ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , May 31, 2019 /CNW/ - Virtual Investor Conferences and KCSA Strategic Communications today announced ...

  • CNW Group2 months ago

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

    Expands to second jurisdiction on closing of agreement with Dayacann to enter Chilean medical cannabis market Signs binding letter of intent to acquire NettaGrowth, securing first medical THC and CBD cannabis ...

  • CNW Group2 months ago

    Khiron Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF

    TORONTO, May 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce today its addition to the MJ ETFMG Alternative Harvest ETF (NYSE:MJ - News) (the "Fund"), a fund with approximately US$1.22 billion in assets currently under management. This represents an important development for the Company as it advances its strategy as a Latin American cannabis company with global growth. The Fund tracks the Prime Alternative Harvest Index, designed to measure the performance of companies within the cannabis ecosystem benefiting from global medicinal and recreational cannabis legalization.

  • CNW Group2 months ago

    Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

    TORONTO, May 28, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce that it has closed today its previously announced "bought deal" short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering"). A total of 9,914,150 Common Shares were sold at a price of $2.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $28,751,035 (including the exercise in full of the over-allotment option).

  • CNW Group2 months ago

    Khiron Provides Update on Transaction to Acquire NettaGrowth

    TORONTO, May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition.

  • CNW Group2 months ago

    Khiron Mails and Files Circular Relating to its Annual General and Special Meeting of Shareholders

    Proxy voting deadline is May 29, 2019 at 11 a.m. (Toronto time). Board of Directors recommends that Shareholders vote FOR all resolutions. TORONTO, May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "Meeting Materials") to Khiron's shareholders ("Shareholders") in connection with the annual general and special meeting of Shareholders (the "Meeting").

  • CNW Group3 months ago

    /C O R R E C T I O N from Source -- Khiron Life Sciences Corp./

    In the news release, Khiron Life Sciences Enters into $25 Million Bought Deal Equity Financing, issued 06-May-2019 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the first paragraph, last sentence, should read "Common Share of $2.90" rather than "Common Share of $3.00" as originally issued inadvertently. TORONTO, May 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, announced today that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, 8,621,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.90 (the "Issue Price") for gross proceeds of $25,000,900 (the "Offering").

  • CNW Group3 months ago

    Khiron Life Sciences Reports 2018 Fiscal Year End Results and Provides Corporate Update

    Secured approximately $40 million of investment capital for cultivation site construction, product development and distribution Became the first Colombian cannabis company to list on the TSX Venture Exchange ...

  • Khiron Gets Kuida® Into Another 150 Stores
    CNW Group3 months ago

    Khiron Gets Kuida® Into Another 150 Stores

    TORONTO, April 30, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has signed a distribution agreements for its Kuida® cosmeceutical brand with Cafam, a leading Colombian drugstore chain. This agreement further expands the brands points of sales In combination with the previous announced distribution arrangements this agreement further expands the brands retail and e-commerce points of sales in Colombia.